跳至主要内容
临床试验/NCT01897493
NCT01897493已完成1 期

Effect of Evacetrapib on the Pharmacokinetics of Digoxin in Healthy Subjects

Eli Lilly and Company1 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2013年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
16
试验地点
1
主要终点
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Digoxin

研究概览

简要总结

The main purpose of this study is to determine how much digoxin gets into the blood stream and how long it takes the body to get rid of it when given with the study drug evacetrapib. This study will also look at the effect of evacetrapib on the removal of digoxin from the body by the kidneys. Information about any side effects that may occur will be collected. This study will last approximately 33 days for each participant, not including screening.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Overtly healthy males and females (of non-childbearing potential)
  • Have a body mass index of 18 to 32 kilograms per square meter (kg/m^2)
  • Normal renal function

排除标准

  • Participants who currently smoke or use tobacco or nicotine products

研究组 & 干预措施

Digoxin

Active Comparator

0.5 milligram (mg) digoxin administered orally once daily (QD) on Day 1

干预措施: Digoxin (Drug)

Evacetrapib + Digoxin

Experimental

130 mg evacetrapib administered orally, QD for 14 days (Days 6 through 19) with a single oral dose of 0.5 mg digoxin coadministered on Day 15

干预措施: Evacetrapib (Drug)

Evacetrapib + Digoxin

Experimental

130 mg evacetrapib administered orally, QD for 14 days (Days 6 through 19) with a single oral dose of 0.5 mg digoxin coadministered on Day 15

干预措施: Digoxin (Drug)

结局指标

主要结局

Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Digoxin

时间窗: Periods 1 and 2: digoxin predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours after administration of digoxin

PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-∞) of Digoxin

时间窗: Periods 1 and 2: digoxin predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours after administration of digoxin

PK: Time of Maximum Observed Drug Concentration (Tmax) of Digoxin

时间窗: Periods 1 and 2: digoxin predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours after administration of digoxin

次要结局

  • Renal Clearance (CLr) of Digoxin(Periods 1 and 2: digoxin predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours after administration of digoxin)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验